A Phase IV, Open-label, Single-group, Single-dose Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
Latest Information Update: 05 Dec 2025
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Alopecia areata; Crohn's disease; Cutaneous lupus erythematosus; Discoid lupus erythematosus; Erythrodermic psoriasis; Hidradenitis suppurativa; Lupus nephritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Sjogren's syndrome; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 16 Dec 2024 Status changed from not yet recruiting to completed.
- 04 Jul 2024 New trial record